These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer. Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996 [TBL] [Abstract][Full Text] [Related]
10. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status. Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604 [TBL] [Abstract][Full Text] [Related]
11. Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476 [No Abstract] [Full Text] [Related]
12. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. Kumarasamy VM; Shin YJ; White J; Sun D BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103 [TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of a novel cell line of medullary thyroid carcinoma from a dog. Okano K; Uematsu Y; Nibe K; Yamashita M; Suzuki S; Uchida K; Ono K; Hirao H In Vitro Cell Dev Biol Anim; 2019 Aug; 55(7):559-566. PubMed ID: 31144267 [TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin. Zhou Q; Yue S; Cheng Y; Jin J; Xu H Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629 [TBL] [Abstract][Full Text] [Related]
15. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. Faggiano A; Modica R; Severino R; Camera L; Fonti R; Del Prete M; Chiofalo MG; Aria M; Ferolla P; Vitale G; Pezzullo L; Colao A Endocrine; 2018 Oct; 62(1):46-56. PubMed ID: 29572709 [TBL] [Abstract][Full Text] [Related]
16. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma. Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802 [TBL] [Abstract][Full Text] [Related]
17. RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma. Wang S; Wang B; Xie C; Ye D Endocr Pathol; 2019 Dec; 30(4):297-304. PubMed ID: 31494787 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma. Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050 [TBL] [Abstract][Full Text] [Related]
19. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. Baldini E; Arlot-Bonnemains Y; Sorrenti S; Mian C; Pelizzo MR; De Antoni E; Palermo S; Morrone S; Barollo S; Nesca A; Moretti CG; D'Armiento M; Ulisse S BMC Cancer; 2011 Sep; 11():411. PubMed ID: 21943074 [TBL] [Abstract][Full Text] [Related]
20. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma. Alqahtani T; Kumarasamy VM; Huczyński A; Sun D Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]